Zoya Marriott

Vice President

Contact

  • Boston

Education

Zoya Marriott coleads Cornerstone Research’s life sciences practice. Dr. Marriott has extensive experience in litigation matters in the life sciences industry, with an emphasis on intellectual property, reimbursement, and antitrust issues. She has worked with attorneys and testifying experts in all phases of the litigation process, including the preparation and submission of expert reports, deposition, and trial.

Within the life sciences industry, Dr. Marriott has conducted research for a large number of Hatch-Waxman disputes, analyzing indicators of commercial success and the nexus between commercial success and relevant patents for branded drugs. She has evaluated the nexus between commercial success and patent claims in the matters related to composition, formulation, and method of use patents. In addition, she has supported clients and experts in preparing for preliminary injunction filings.

Dr. Marriott also has expertise in average wholesale price (AWP) litigation matters for both branded and generic manufacturers. In these matters, Dr. Marriott analyzed manufacturers’ price reporting practices, payors’ reimbursement policies, and their impact on pharmacies.

Dr. Marriott has also investigated issues in several antitrust matters stemming from the settlements between branded companies and would-be generic competitors; analyzed class certification and damages issues in cases with allegations of off-label marketing and product misrepresentation; conducted survey research to evaluate influence of alleged off-label promotions relative to other factors on physicians’ prescribing behavior; and examined damages and contract issues in breach of contract matters. In addition to her experience on cases in the life sciences industry, she has also examined intellectual property, antitrust, marketing, and valuation questions in other industries.

Press Release

Cornerstone Research Promotes Seven to Vice President and Principal

Case

Breach of Contract for a Branded Drug

  • “Does Generic Entry Always Increase Consumer Welfare?,” Food and Drug Law Journal, 2012
  • “Interpreting Stock Reactions to Reverse-Payment Settlements,” Law360, February 2015
  • “A State of the Union on Key Legal Developments Impacting the Life Sciences Industry in the Last Year,” Women Leaders in Life Sciences Law 2019, 25 July 2019
  • “Recent Business Trends within the Life Sciences Industry,” Women Leaders in Life Sciences Law 2018, 26 July 2018
  • “Considering the ‘But-for’ World in Reverse Payment Litigation,” American Bar Association Section of Intellectual Property Law, 9 December 2016